Novel blood serum assay to diagnose neurodegenerative diseases

Written By :  Isra Zaman
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-05-30 03:45 GMT   |   Update On 2023-05-30 08:46 GMT
Advertisement

Synucleinopathies are a group of neurodegenerative diseases caused by the abnormal accumulation a-synuclein, a protein normally found in the brain and neurons. Incorrect folding of α-synuclein leads to formation of ‘seeds’, which attract more α-synuclein proteins to form larger clumps. Although, α-synuclein seeds have been found in various tissues and blood of patients with synucleinopathies, its potential as a biomarker is ambiguous.

Recently, in a study published in Nature Medicine Japanese researchers present a novel assay that can efficiently detect α-synuclein seeds from a patient’s serum.

In this assay, named immunoprecipitation-based real-time quaking-induced conversion (IP/RT-QuIC), the α-synuclein seeds are isolated from the patient’s serum through immunoprecipitation followed by rapid amplification by real-time quaking-induced conversion. This method is highly sensitive, as it can detect serum α-synuclein seed concentrations as small as 1000pg/ml. This comes as great news since most existing diagnostic methods require cerebrospinal fluid for synuclein detection.

The research team demonstrated that IP/RT-QuIC detected α-synuclein seeds efficiently in patients with neurodegenerative diseases and could distinguish them from people without degenerative diseases (controls). Next, they studied the structural properties of the amplified seeds using4 transmission electron microscopy. They observed that the synuclein seed structure varied with the type of synucleinopathy.5 Parkinson’s disease and dementia with Lewy bodies seeds showed paired filaments whereas MSA seeds had two distinct structures – twisted and straight filaments. This finding confirmed that IP/RT-QuIC coupled with TEM can differentiate between synucleinopathies based on disease specific seed structure.

Ref:Propagative α-synuclein seeds in the se are a group of neurodegenerative diseases caused by the abnormal accumulation α-synuclein, a protein normally found in the brain and neurons. Incorrect folding of α-synuclein leads to formation of ‘seeds’, which attract more α-synuclein proteins to form larger clumps.2 Although, α-synuclein seeds have been found in various tissues and blood of patients with synucleinopathies, its potential as a biomarker is ambiguous.

Recently, in a study published in Nature Medicine Japanese researchers present a novel assay that can efficiently detect α-synuclein seeds from a patient’s serum.

In this assay, named immunoprecipitation-based real-time quaking-induced conversion (IP/RT-QuIC), the α-synuclein seeds are isolated from the patient’s serum through immunoprecipitation followed by rapid amplification by real-time quaking-induced conversion. This method is highly sensitive, as it can detect serum α-synuclein seed concentrations as small as 1000pg/ml. This comes as great news since most existing diagnostic methods require cerebrospinal fluid for synuclein detection.

3The research team demonstrated that IP/RT-QuIC detected α-synuclein seeds efficiently in patients with neurodegenerative diseases and could distinguish them from people without degenerative diseases (controls). Next, they studied the structural properties of the amplified seeds using4 transmission electron microscopy. They observed that the synuclein seed structure varied with the type of synucleinopathy.5 Parkinson’s disease and dementia with Lewy bodies seeds showed paired filaments whereas MSA seeds had two distinct structures - twisted and straight filaments. This finding confirmed that IP/RT-QuIC coupled with TEM can differentiate between synucleinopathies based on disease specific seed structure.

Reference:

Propagative α-synuclein seeds in the serum of patients with synucleinopathies,Nature Medicine, DOI 10.1038/s41591-023-02358-9 

Full View
Tags:    
Article Source : Nature Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News